Clinical trials: Non-small Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without…
- Trial name
- TROPION-Lung17 (NCT07291037)
- Testing
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Where
- 206 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China
This is a multicenter, prospective, longitudinal observational study designed to evaluate the patient-reported outcomes and safety profiles of patients with ALK positive advanced Non-Small Cell Lung Cancer (NSCLC) who received…
- Trial name
- NCT06586801
- Testing
- Patient-reported outcome
- Volunteers
- 800 people
- Sponsor
- Shanghai East Hospital
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- LEAP-007 (NCT04676412)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 17 sites in China
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
This study will assess the prevalence of epidermal growth factor receptor (EGFR) mutations in newly diagnosed patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT01250119
- Testing
- erlotinib [Tarceva]
- Where
- 22 sites in United Kingdom
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Non-small Cell Lung Cancer (NSCLC)
A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)
The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor…
- Trial name
- MEANING-20 (NCT05863819)
- Testing
- No Intervention
- Where
- China
- Sponsor
- Takeda
Non-small Cell Lung Cancer
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with NSCLC (clinical trials.gov ref. NCT02183883). .
- Trial name
- DARWINII (NCT02314481)
- Testing
- MPDL3280A, Vemurafenib, Alectinib
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Lung Cancer
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of onartuzumab that can be given with erlotinib and standard chemoradiation (paclitaxel and carboplatin) to patients with NSCLC.
- Trial name
- NCT02044601
- Testing
- Onartuzumab, Erlotinib, Paclitaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Non-small-cell Lung Cancer
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
This is a single-arm, open, multicenter phase II clinical study to evaluate the efficacy and safety of HL-085 capsules combined with Vemurafenib in the treatment of BRAF V600E mutated patients with unresectable locally advanced…
- Trial name
- NCT05900219
- Testing
- HL-085+Vemurafenib
- Volunteers
- 75 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Non-small Cell Lung Cancer Patients
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)
PIONeeR study is a prospective, multicenter study without administration of an investigational product. The promotion and funding will be done by the Assistance Publique Hôpitaux de Marseille (APHM), the coordination by AMU.
- Trial name
- PIONeeR (NCT03493581)
- Testing
- BIOPSY, blood-sampled, feces samples
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Lung Cancer
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT01207011
- Testing
- Amrubicin hydrocloride, Docetaxel
- Where
- Japan
- Volunteers
- 202 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Non Small Cell Lung Cancer
MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Lung cancer is one of the most prevalent and lethal neoplasias in the world. Currently used chemotherapy regimens have been disappointing in improving overall survival.
- Trial name
- NCT01628471
- Testing
- decitabine in combination with genistein
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Uman Pharma
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as first line treatment for…
- Trial name
- NCT04323436
- Testing
- Spartalizumab, Capmatinib
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Neoadjuvant Itraconazole in Non-small Cell Lung Cancer
The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.
- Trial name
- NCT02357836
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- ANVIL (NCT02595944)
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 884 sites in United States
- Volunteers
- 903 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
This is a multicenter, open-label, randomized phase 1 study of escalating doses of Tarceva in patients with advanced NSCLC who currently smoke. Part I will establish the maximum tolerated dose (MTD) of Tarceva in current smokers.
- Trial name
- NCT00294736
- Testing
- Tarceva
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 57 people
- Sponsor
- OSI Pharmaceuticals
Lung Neoplasms
Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China
The purpose of this study is to verify clinical utility of a simple blood test comprising of four protein- based markers for risk stratification of patients presenting symptoms related to lung cancer.
- Trial name
- LCBP (NCT01928836)
- Where
- 6 sites in China
- Volunteers
- 764 people
- Sponsor
- Bai Chunxue
Lung Cancer (NSCLC)
Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
This is a prospective, randomized phase II study evaluating concurrent chemoradiotherapy combined with full-course immunotherapy or consolidative immunotherapy in patients with unresectable, locally advanced non-small cell lung…
- Trial name
- NCT07874464
- Testing
- Induction chemoimmunotherapy, radiotherapy, Concurrent Chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
This was a multicenter, open-label phase 2 study. This study aimed to evaluate the efficacy and safety of JMT101 combined with Osimertinib in participants with local advanced or metastatic non-small-cell lung cancer harbouring…
- Trial name
- NCT06391944
- Testing
- JMT101 Injection, Osimertinib tablet
- Where
- China
- Volunteers
- 161 people
- Sponsor
- Shanghai JMT-Bio Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.